However, since the discovery of the importance of transcellular tau spreading in the progression of tau pathology in AD, the focus has been placed on tau-based immunotherapy (both passive and active), an approach to target (mostly but not only) extracellular tau, thereby stopping the spreading process. The gene discussed is MAPT; the disease is Alzheimer disease.